Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shanghai Launches New Exchange for High-Tech Companies Including Biopharmas

publication date: Jun 14, 2019

China officially launched the Shanghai Exchange's new Science and Technology Innovation Board (STIB) with news that 119 companies, including 27 biopharmas, have already signed up to IPO on the new exchange. For China, the STIB accomplishes two goals: high tech companies that are not yet profitable can list on a mainland exchange for the first time, and STIB IPOs will be registration-based. That means China regulators will not set the prices of IPOs, nor will they control the schedule and/or number of listing companies. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China